Aliprandi A.,Radiology Unit |
Sconfienza L.M.,Radiology Unit |
Randelli P.,Orthopedic Surgery Unit |
Randelli P.,University of Milan |
And 5 more authors.
European Journal of Radiology | Year: 2011
Objective: We evaluated safety and potential diagnostic value of magnetic resonance (MR) imaging of the knee treated with medial unicompartmental arthroplasty (MUA). Methods: The treated knee of 8 patients who underwent MUA was studied with four different 1.5-T MR sequences. Two radiologists independently evaluated eleven anatomical items using a score from 0 (not assessable) to 3 (completely assessable). The sum of the scores for each sequence was divided by the potential maximal sum, obtaining a percentage visibility index (PVI) for each item. Results: No adverse effect was reported during or within 30 min after the exam. Posterior cruciate ligament was unseen in all patients by both observers. The following PVIs were reported for the remaining ten items: femoral-patellar relationship 83-100%; femoral-patellar cartilage 92-100%; Hoffa's fat pad 75-92%; patellar ligament 79-100%; lateral meniscus 100%; femoral-tibial lateral joint 100%; lateral collateral ligament 96-100%; anterior cruciate ligament 54-83%; femoral-tibial lateral cartilages 92-100%; posterolateral corner 100%. Agreement between readers was found in 331/352 (94%) evaluations (k = 0.74-0.78). Conclusions: MR imaging after MUA offers a safe and reproducible evaluation of residual knee anatomy except for cruciate ligament, and can be used to follow-up these patients. © 2010 Elsevier Ireland Ltd.
Boutasta T.,Orthopedic Surgery Unit |
Nekhla A.,Cardiothoracic Surgery Unit
Injury Extra | Year: 2013
The posterior variety of sternoclavicular joint dislocation is an uncommon condition accounting for 0.06% of all shoulder injuries, the diagnosis is often missed, but frequently associated to a high morbidity by compromising the great vessels, trachea, oesophagus, or lungs. Although the majority of these complications are observed in acute presentation, few reports noted late complications with chronic unreduced dislocation. © 2013.
Tone A.,Gustave Dron Hospital |
Nguyen S.,Gustave Dron Hospital |
Devemy F.,Diabetology Unit |
Topolinski H.,Diabetology Unit |
And 6 more authors.
Diabetes Care | Year: 2015
OBJECTIVE: Little is known about the optimal duration of antibiotic therapy for diabetic foot osteomyelitis (DFO). This study sought to compare the effectiveness of 6 versus 12 weeks of antibiotic therapy in patients with DFO treated nonsurgically (i.e., antibiotics alone). RESEARCH DESIGN AND METHODS: This was a prospective randomized trial comparing 6-versus 12-week duration of antibiotic treatment. Remission of osteomyelitis during the monitoring period was defined as complete and persistent (>4 weeks) healing of the wound (if present initially), absence of recurrent infection at the initial site or that of adjacent rays, and no need for surgical bone resection or amputation at the end of a follow-up period of at least 12 months after completion of antibiotic treatment. RESULTS: Forty patients followed at five French general hospitals were randomized between January 2007 and January 2009, with 20 treated for 6 weeks and 20 treated for 12 weeks with antibiotics. The two groups were comparable for all variables recorded at inclusion in the study. Remission was obtained in 26 (65%) patients, with no significant differences between patients treated for 6 versus 12 weeks (12/20 vs. 14/20, respectively; P = 0.50). We did not identify any significant parameters associated with patient outcome. Fewer patients treated for 6 weeks experienced gastrointestinal adverse events related to antimicrobial therapy compared with patients treated for 12 weeks (respectively, 15 vs. 45%; P = 0.04). CONCLUSIONS: The present multicenter prospective randomized study provides data suggesting that 6-week duration of antibiotic therapy may be sufficient in patients with DFO for whom nonsurgical treatment is considered. © 2015 by the American Diabetes Association.
Chen-An P.,Cartilage Biology and Biomarkers |
Andreassen K.V.,Bone Biology and Pharmacology |
Henriksen K.,Bone Biology and Pharmacology |
Li Y.,Orthopedic Surgery Unit |
And 2 more authors.
PLoS ONE | Year: 2012
Objective: Salmon calcitonin has chondroprotective effect both in vitro and in vivo, and is therefore being tested as a candidate drug for cartilage degenerative diseases. Recent studies have indicated that different chondrocyte phenotypes may express the calcitonin receptor (CTR) differentially. We tested for the presence of the CTR in chondrocytes from tri-iodothyronin (T3)-induced bovine articular cartilage explants. Moreover, investigated the effects of human and salmon calcitonin on the explants. Methods: Early chondrocyte hypertrophy was induced in bovine articular cartilage explants by stimulation over four days with 20 ng/mL T3. The degree of hypertrophy was investigated by molecular markers of hypertrophy (ALP, IHH, COLX and MMP13), by biochemical markers of cartilage turnover (C2M, P2NP and AGNxII) and histology. The expression of the CTR was detected by qPCR and immunohistochemistry. T3-induced explants were treated with salmon or human calcitonin. Calcitonin down-stream signaling was measured by levels of cAMP, and by the molecular markers. Results: Compared with untreated control explants, T3 induction increased expression of the hypertrophic markers (p<0.05), of cartilage turnover (p<0.05), and of CTR (p<0.01). Salmon, but not human, calcitonin induced cAMP release (p<0.001). Salmon calcitonin also inhibited expression of markers of hypertrophy and cartilage turnover (p<0.05). Conclusions: T3 induced early hypertrophy of chondrocytes, which showed an elevated expression of the CTR and was thus a target for salmon calcitonin. Molecular marker levels indicated salmon, but not human, calcitonin protected the cartilage from hypertrophy. These results confirm that salmon calcitonin is able to modulate the CTR and thus have chondroprotective effects. © 2012 Chen-An et al.
Corrado A.,University of Foggia |
Neve A.,University of Foggia |
Macchiarola A.,Orthopedic Surgery Unit |
Gaudio A.,University of Foggia |
And 2 more authors.
Journal of Rheumatology | Year: 2013
Objective. To evaluate the expression of Dickkopf-1 protein factor (DKK-1), DKK-2, and β-catenin, components of the Wnt pathway, in human osteoarthritic (OA) and osteoporotic (OP) osteoblasts and to correlate it to cell metabolic activity, proliferation, and receptor activator of nuclear factor-κB ligand/osteoprotegerin (RANKL/OPG) expression. Methods. Primary human osteoblast cultures were obtained from healthy, OA, and OP donors. In each cell population we evaluated DKK-1, DKK-2, nonphosphorylated β-catenin and RANKL/OPG expression, osteocalcin and alkaline phosphatase (ALP) synthesis, and cell proliferation, both in basal condition and after vitamin D3 stimulation. Results. DKK-1 and DKK-2 showed opposite patterns of expression in OA and OP osteoblasts. The RANKL/OPG ratio was significantly higher in the OP group because of a greater expression of RANKL, whereas it was significantly lower in the OA group because of a higher expression of OPG. Treatment with vitamin D3 increased the RANKL/OPG ratio and DKK-2 expression and reduced DKK-1 expression in each cell population, but did not affect β-catenin levels. Both osteocalcin and ALP production and cell proliferation were enhanced in OA cells and reduced in the OP ones. Conclusion. These data confirm that OA and OP are characterized by opposite bone changes, consisting of reduced bone remodeling processes with increased osteoblast activity in OA, and enhanced bone resorptive activity with reduction of osteoblast metabolism in OP, and suggest that the Wnt pathway is involved in the pathogenesis of both diseases. The Journal of Rheumatology Copyright © 2013. All rights reserved.